Observational studyBMC oral health2026
Survival of dental implants in patients undergoing chemotherapy: an observational study.
Observational study in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are a limited number of clinical studies in indexed literature that have assessed the survival of dental implants among patients with systemic cancers undergoing chemotherapy. The present observational study aimed to assess the survival of dental implants in patients undergoing chemotherapy. MATERIALS AND
methodsThe primary outcome variable was the survival of dental implants in patients undergoing chemotherapy. Participants were categorized into two groups: Test Group, consisting of patients who had undergone dental implant placement and were currently receiving chemotherapy for systemic cancers, and the Control Group, comprising systemically healthy individuals who had undergone dental implant therapy (DAT). The peri-implant modified plaque and bleeding indices (mPI and mBI), probing depth (PD), and crestal bone loss (CBL) were assessed. Data normality was assessed and group comparisons were done. Level of significance was set at P < 0.05.
resultsTwenty-five (14 males and 11 females) and 28 (15 males and 13 females) individuals were included in the test and control groups, respectively. The mean age of individuals in the test and control groups were 69.6 ± 3.7 and 66.1 ± 4.7 years, respectively. Individuals in the test group were diagnosed with cancer 1.3 ± 0.3 years ago and were currently being treated with 5-fluorouracil and carboplatin in three-cycles. In the test and control groups, 15 and 35 implants, which were in function for 2.4 ± 0.6 and 5.7 ± 0.2 years, respectively were subjected to clinical and radiographic evaluation. There was no difference in the mean scores of mPI, mBI, PD and CBL in the test and the control group. In the test control group, the implant survival rates were 60% and 100%, respectively.
conclusionChemotherapy is not an absolute contraindication for DAT; however, the long-term survival of implants in these individuals is uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.